The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform

Am Cesinaro - One of the best experts on this subject based on the ideXlab platform.

Filippo Fantini - One of the best experts on this subject based on the ideXlab platform.

Metin Özdemirli - One of the best experts on this subject based on the ideXlab platform.

  • Clear cell Sarcoma in unusual sites mimicking metastatic melanoma
    World journal of clinical oncology, 2019
    Co-Authors: Ifeyinwa E. Obiorah, Metin Özdemirli
    Abstract:

    Background Clear cell Sarcoma is an aggressive rare malignant neoplasm with morphologic and immunohistochemical similarities to malignant melanoma. Both disease entities display melanin pigment and melanocytic markers, making differentiation between the two difficult. Although clear cell Sarcoma cases in the literature have mainly involved deep soft tissues of the extremities, trunk or limb girdles, we report here two cases of primary clear cell Sarcoma in unusual sites and describe their clinicopathologic findings. Case summary The first case involves a 37-year-old female, who presented with jaw pain and a submandibular mass. The second case involves a 33-year-old male, who presented with back pain and a thoracic spine tumor. Both cases showed tumors with diffuse infiltration of neoplastic cells that were positive for melanocytic markers, and in both cases this finding led to an initial diagnosis of metastatic melanoma. However, further analysis by fluorescence in situ hybridization (commonly known as FISH) showed a rearrangement of the EWS RNA binding protein 1 (EWSR1) gene on chromosome 22q12 in both patients, confirming the diagnosis of clear cell Sarcoma. Conclusion Distinction between clear cell Sarcoma and malignant melanoma can be made by FISH, particularly in cases of unusual tumor sites.

  • Primary Clear Cell Sarcoma of the Dermis Mimicking Malignant Melanoma
    Galenos Publishing House, 2018
    Co-Authors: Ifeyinwa E. Obiorah, Pauline Brenholz, Metin Özdemirli
    Abstract:

    Background: Clear cell Sarcoma is a rare malignant soft tissue neoplasm that typically involves tendons and aponeurosis. Clear cell Sarcoma in the dermis is an extremely rare occurrence, and it is difficult to differentiate between this neoplasm and dermal malignant melanoma because they have similar morphologic and immunohistochemical features. Although rare, clear cell Sarcoma of the skin typically occurs in the extremities. To our knowledge, there are no reported cases of primary clear cell Sarcoma of the skin occurring in the neck. Here, we report an unusual case of clear cell Sarcoma arising in the skin of the neck. Case Report: A 43-year-old female presented with a right neck lesion. Histologic sections of the lesion showed a nodular proliferation of spindle cells with pale cytoplasm with epithelioid features involving the entire dermis with no epidermal component. The tumour cells were positive for melanocytic markers, including S100 and Human Melanoma Black 45, which led to an initial diagnosis of malignant melanoma. Fluorescence in situ hybridization showed a rearrangement of the EWSR1 gene on chromosome 22q12, which led to a diagnosis of primary clear cell Sarcoma in the skin. Conclusion: Because the treatments for clear cell Sarcoma and conventional melanoma are different, fluorescence in situ hybridization for EWSR1 should be performed in any dermal lesions with melanocytic features that do not have an in situ component

Sarah L. Blair - One of the best experts on this subject based on the ideXlab platform.

  • Clear cell Sarcoma in the era of sentinel lymph node mapping
    Journal of surgical oncology, 2004
    Co-Authors: Waddah B. Al-refaie, Mir Wasif Ali, David Chu, Isaac Benjamin Paz, Sarah L. Blair
    Abstract:

    Clear cell Sarcoma of the tendons and aponeuroses (CCSTA) are rare aggressive soft tissue tumors with tendency for lymph nodes dissemination. Lymph node involvement is a correlate for prognosis. We present three patients with CCSTA in whom simultaneous sentinel lymph biopsy (SLNB) and resection was performed. Sentinel lymph node mapping may have a role in clear cell Sarcoma from a prognostic standpoint. Further investigations are needed for validation.

Andrew E. Horvai - One of the best experts on this subject based on the ideXlab platform.

  • Utility of CD117 Immunoreactivity in Differentiating Metastatic Melanoma From Clear Cell Sarcoma
    Archives of Pathology & Laboratory Medicine, 2006
    Co-Authors: Joaquin J. Garcia, Miranda J. Kramer, Zachary B. Mackey, Richard J. O'donnell, Andrew E. Horvai
    Abstract:

    Abstract Context.—Clear cell Sarcoma is a malignant soft tissue tumor with melanocytic differentiation. Molecular methods are sometimes necessary to identify the unique t(12; 22)(q13;q12) translocation and differentiate clear cell Sarcoma from melanoma. Objective.—To determine whether CD117 immunoreactivity may be useful in separating melanoma from clear cell Sarcoma. Design.—We identified 20 tumors listed in our surgical pathology files that were diagnosed as clear cell Sarcoma or in which clear cell Sarcoma was strongly considered. These were tested for the presence of the t(12;22) translocation by reverse transcriptase/polymerase chain reaction and sequencing from paraffin-embedded tissue. Tumors with a t(12;22) translocation were immunostained with an antibody to CD117 and compared with 16 similarly stained metastatic melanomas. Results.—Twelve tumors from 9 patients demonstrated t(12;22). No metastatic melanomas demonstrated t(12;22). None of the 12 clear cell Sarcomas showed membrane or cytoplasmic staining for CD117. Conversely, 10 (63%) of 16 metastatic melanomas were, at least focally, positive for CD117; this difference was significant (P < .001). Interestingly, 3 tumors in which clear cell Sarcoma was initially considered as a diagnosis, but which lacked t(12;22), were also positive for CD117. Conclusions.—Reverse transcriptase/polymerase chain reaction, performed on paraffin-embedded tissue, is a useful, rapid tool for identifying the presence of t(12;22) in clear cell Sarcoma. The CD117 immunoreactivity may prove useful in the differential diagnosis of deep soft tissue or visceral lesions with melanocytic differentiation; positive staining results exclude clear cell Sarcoma, but are compatible with metastatic melanoma.

  • Utility of CD117 immunoreactivity in differentiating metastatic melanoma from clear cell Sarcoma.
    Archives of pathology & laboratory medicine, 2006
    Co-Authors: Joaquin Garcia, Miranda J. Kramer, Zachary B. Mackey, Richard J. O'donnell, Andrew E. Horvai
    Abstract:

    Abstract Context.—Clear cell Sarcoma is a malignant soft tissue tumor with melanocytic differentiation. Molecular methods are sometimes necessary to identify the unique t(12; 22)(q13;q12) translocation and differentiate clear cell Sarcoma from melanoma. Objective.—To determine whether CD117 immunoreactivity may be useful in separating melanoma from clear cell Sarcoma. Design.—We identified 20 tumors listed in our surgical pathology files that were diagnosed as clear cell Sarcoma or in which clear cell Sarcoma was strongly considered. These were tested for the presence of the t(12;22) translocation by reverse transcriptase/polymerase chain reaction and sequencing from paraffin-embedded tissue. Tumors with a t(12;22) translocation were immunostained with an antibody to CD117 and compared with 16 similarly stained metastatic melanomas. Results.—Twelve tumors from 9 patients demonstrated t(12;22). No metastatic melanomas demonstrated t(12;22). None of the 12 clear cell Sarcomas showed membrane or cytoplasmic ...